相关实验视频

Updated: Jan 11, 2026

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

开发一种针对性BioPROTAC降解剂,对错误折叠的SOD1具有选择性

Christen G Chisholm¹, Rachael Bartlett², Mikayla L Brown²

¹Molecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia. christen@uow.edu.au.

Nature communications

|November 10, 2025

概括

这项研究引入了一种新型的生物蛋白溶解向金氏体 (BioPROTAC) 来降解错误折叠的超氧化物失致酶1 (SOD1) 蛋白,这是肌缩侧硬化症 (ALS) 的关键因素. 在ALS小鼠模型中,BioPROTAC疗法有效地延迟了疾病的进展.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
生物化学生物化学

背景情况:

错误折叠的蛋白质积累是神经退行性疾病的核心,如ALS.
针对这些动态错折的蛋白质进行治疗仍然是一个重大挑战.
超氧化解突变酶1 (SOD1) 突变与家族ALS有关,导致有毒蛋白质聚合.

研究的目的:

开发和验证一种新的治疗策略,针对ALS中错误折叠的SOD1变体.
评估生物蛋白质溶解向木乃伊 (BioPROTAC) 在降解有毒SOD1物种中的有效性.
评估BioPROTACs在ALS小鼠模型中延迟神经退行症的治疗潜力.

主要方法:

设计和选SOD1特异性体内酶和E3结合酶,以实现最佳的BioPROTAC构造.
利用CRISPR/Cas9技术生成一个BioPROTAC转基因小鼠系列.
在SOD1^G93A^小鼠中评估了疾病进展,运动神经元存活率,SOD1聚合和神经肌肉结合完整性.

主要成果:

鉴定了一种能够降解多种疾病相关的SOD1变体并防止细胞聚合的BioPROTAC.
证明转基因小鼠中的BioPROTAC表达在SOD1^G93A^ALS模型中显著延迟疾病进展.
在接受治疗的小鼠中观察到运动神经元的保护,减少不溶性SOD1,并保留神经肌肉结.

结论:

生物PROTACs代表了一个可行的治疗平台,用于针对性降解神经毒性错误折叠蛋白质.
这种方法对治疗神经退行性疾病,如ALS,通过清除疾病特异性蛋白质聚合物的治疗有希望.
进一步开发BioPROTACs可以为治疗蛋白质病变提供新的途径.

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

相关概念视频

Export of Misfolded Proteins out of the ER

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...